During the COVID19 pandemic, we realised the lack of a state-of-the-art research laboratory facility that would allow us to work on Biosafety Level 1/2 pathogen and associated human clinical samples. To address this infrastructure gap, we, Research Institute for Bioscience and Biotechnology (RIBB) and Kathmandu Research Institute for Biological Sciences (KRIBS), came together to co-establish a laboratory facility that stands on the global biological safety level 2 qualification. Currently, we are working together to study different infectious diseases in this facility, and we are also training young scientists so as to sustain the research culture we create. We named it “Biomedicum campus”, where researchers and students from both institute come together to share ideas and learn the science together.
Meet the team
Mitesh Shrestha (MSc. Biotechnology)
Mitesh heads the laboratory operations at RIBB and oversees the BSL2 laboratory.
Minu Singh (MSc. Biotechnology)
Minu is one of the founding members of KRIBS and is a Research Faculty at the Department of Infection and Immunology, who also oversees the BSL2 laboratory.
Ongoing Research Studies
Characterization of anti-HIV antibodies for their role in immune effector (neutralizing and Fc mediated) functions
This study aims to characterise the anti-HIV antibodies isolated from HIV patients, to understand the immune-activating functions through the antibody’s Fc constant region. We utilize the monocytes and natural killer cells to assay for antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent neutralization (ADN) at the BSL2 laboratory. This study is funded through European Research Council and human ethics approval has been granted from Nepal Health Research Council.
Principal Investigator: Anurag Adhikari (Department of Infection and Immunology, Kathmandu Research Institute for Biological Sciences)